Ossenkoppele, G J <br/><br/>
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.  [electronic resource] 

 -  Leukemia  07 2020 
 - 1751-1759 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/s41375-020-0725-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Cytarabine--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Induction Chemotherapy--mortality<br/>Lenalidomide--administration & dosage<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Male<br/>Myelodysplastic Syndromes--drug therapy<br/>Prognosis<br/>Remission Induction<br/>Survival Rate